Clinical Trials in New York

Showing 10121-10140 of 19,464 trials

Evaluating the Safety and Immunogenicity of an HIV Vaccine (gp145 C.6980) in Healthy, HIV-Uninfected Adults in the United States

NCT03382418

The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of an HIV vaccine (gp145 C.6980) with aluminum hydroxide adjuvant in healthy, HIV-1-uninfected adults in the United States.

HIV Infections

National Institute of Allergy and Infectious Diseases (NIAID)45 participantsStarted Dec 2017

New York, New York, United States • New York, New York, United States • Philadelphia, Pennsylvania, United States

COMPLETEDPhase 2< 1 mile

Safety, Efficacy and Pharmacokinetics of CF-301 vs. Placebo in Addition to Antibacterial Therapy for Treatment of S. Aureus Bacteremia

NCT03163446

The purpose of this study is to evaluate the safety, tolerability, efficacy and pharmacokinetics (PK) of CF-301 in addition to background standard of care (SOC) antibacterial therapy for the treatment of Staphylococcus aureus (S. aureus) bloodstream infections (bacteremia), including endocarditis in adults. Patients will be randomized to receive a single intravenous dose of CF-301 or placebo in addition to SOC antibacterial therapy. Patients will be prescribed standard of care antibiotics selected by the investigators based on their professional experience, practice guidelines and local antibiotic susceptibility information for the treatment of S. aureus bacteremia. CF-301 is a lysin and member of a new class of targeted protein-based antimicrobials that has demonstrated activity against S. aureus in laboratory (in vitro) and animal studies, alone and in addition to conventional antibiotics.

Staphylococcus Aureus BacteremiaStaphylococcus Aureus Endocarditis

ContraFect121 participantsStarted May 2017

Birmingham, Alabama, United States • Sacramento, California, United States • Sylmar, California, United States +75 more locations

Evaluating the Safety and Immunogenicity of an HIV Vaccine (gp145 C.6980) in Healthy, HIV-Uninfected Adults in the United States

Safety, Efficacy and Pharmacokinetics of CF-301 vs. Placebo in Addition to Antibacterial Therapy for Treatment of S. Aureus Bacteremia

Find Trials by Condition in New York

A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder

NSABP Biospecimen Discovery Project

Leveraging Family-Based Assets for Black MSM In House Ball Communities

Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis (PsA) After 16 Weeks of Treatment Compared to Placebo

Fenestrated AAA Endovascular Graft Post-Approval Study

Oxytocin vs. Placebo for the Treatment Hyperphagia in Children and Adolescents With Prader-Willi Syndrome

Phase I/II Study of hLL1-DOX in Relapsed NHL and CLL

Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder

Emotion Recognition Modification for Bipolar Disorder

A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg Fingolimod

A Study of ALKS 3831 in Adults With Schizophrenia

Study of UCART19 in Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia

Study to Assess the Efficacy and Safety of CJM112 in Patients With Inadequately Controlled Severe Asthma

Study of Efficacy of Fevipiprant in Patients With Nasal Polyposis and Asthma

Manipulating the Microbiome in IBD by Antibiotics and FMT

Investigation of the Efficacy of CARDIO Softgels PLUS Best-standard-of-care in the Recovery of Patients With COVID-19

A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 mg Subcutaneous Ofatumumab Injected by Pre-filled Syringe or Autoinjector in Adult RMS Patients

Study to Compare QVM149 and Free Triple Combination of Salmeterol/Fluticasone + Tiotropium